Abranilla, Baby Girl .

HRN: 26-63-00  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/30/2025
AMPICILLIN 250MG (VIAL)
01/30/2025
02/06/2025
IV
35mg
Q 12
PSNB
Waiting Final Action 
01/30/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
01/30/2025
02/06/2025
IV
9 Mg
Q 24
PSNB
Waiting Final Action 
02/08/2025
CEFTAZIDIME 1GM (VIAL)
02/08/2025
02/15/2025
IV
40 Mg
Q12hrs
Sepsis Neonatorum
Waiting Final Action 
02/09/2025
AMPICILLIN 250MG (VIAL)
02/09/2025
02/11/2025
IV
50mg
Q12
Sepsis Neonatorum
Waiting Final Action 
02/12/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/12/2025
03/10/2025
IVTT
110mg
Q12h
PCAP D
Waiting Final Action 
02/16/2025
FLUCONAZOLE 150MG (CAP)
02/16/2025
03/04/2025
ORAL
20 Mg Pptab As LD Then 12 Mg Pptab As Maintenace
Q24
Sepsis
Waiting Final Action 
02/20/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
02/20/2025
02/27/2025
IV
7.5mg
Q8
PSNB
Waiting Final Action 
02/20/2025
MUPIROCIN 2%, 15G (TUBE)
02/20/2025
02/27/2025
TOPICAL
15g
TID
Phlebitis
Waiting Final Action 
03/05/2025
FLUCONAZOLE 2MG/ML, 100ML (VIAL)
03/05/2025
03/11/2025
IV
25mg As LD Then 12mg Q24h
Q24h
Fungal Infection
Waiting Final Action 
03/06/2025
CLARITHROMYCIN 125MG/5ML, 60ML SUSPENSION (BOT)
03/06/2025
03/12/2025
ORAL
0.75ml
Q12
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: